With respect to assay development, quality assurance and, ultimately, clinical adoption, the primary subject of this review, these advantages are critical. Implicit with these advantages, TMAs enable ...
With our MosaiQ AiPlex Celiac Disease microarray already under review by the FDA, today's submission brings us a significant step closer to delivering clinical and economical value to customers in the ...
Decipher score as a predictor of response to treatment intensification in the NRG Oncology-RTOG 0534 (SPPORT) phase III randomized post-prostatectomy salvage radiotherapy trial. Continuous MMAI scores ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results